Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Urologic Diseases 1 Pancreatic Neoplasms 1 Nephritis 1 Neoplasms 1 Melanoma 1 Mastocytosis 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Kidney Diseases 1 Immune System Diseases 1 Hypoxia 1 Glomerulonephritis, IGA 1 Glomerulonephritis 1 Carcinoma, Non-Small-Cell Lung 1 COVID-19 1 Autoimmune Diseases 1

Interventions

Nivolumab 25 pembrolizumab 20 Ipilimumab 15 toripalimab 12 Temozolomide 11 Biopsy 8 Dacarbazine 7 Cyclophosphamide 6 Blood Specimen Collection 6 trametinib 5 fludarabine 5 dabrafenib 5 camrelizumab 5 atezolizumab 5 Gene Expression Profiling 5 Chemotherapy, Adjuvant 5 durvalumab 4 binimetinib 4 aldesleukin 4 Interleukin-2 4 Injections 4 Carboplatin 4 tislelizumab 3 palbociclib 3 encorafenib 3 apatinib 3 Sorafenib 3 Paclitaxel 3 Introns 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Melanoma × Hydroxychloroquine × Clear all

NCT03754179 2021-04-28

COMBI-R2

Universitair Ziekenhuis Brussel

Phase 1/2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡